TP53 and diffuse large B-cell lymphoma: As shown in Figure 6, Pt18 (DLBCL subtype), who achieved PR after four cycles of R-DA-EDOCH treatment, presented an increased VAF of TP53 p.Y87N mutation (TP53 pathway; 0 vs 17.86%), but a decreased VAF of FAT1 p.E1292K mutation (Hippo pathway; 44.74 vs 0%), which might be responsible for partial sensitivity or acquired resistance to R-DA-EDOCH.